Updated guidelines on allogeneic hematopoietic stem cell transplantation for myelofibrosis examine spleen-related ...
GSK added Ojjaara to its portfolio through the acquisition of Sierra in 2022. Credit: Magda Wygralak via Shutterstock. Health ...
Medpage Today on MSN15d
Asymptomatic or Minimally Symptomatic MyelofibrosisAbout 20% of patients with myelofibrosis initially have no symptoms, allowing many cases to exist under the clinical suspicion of primary care clinicians. The need to treat asymptomatic or minimally ...
What do you think is worth looking out for in the future for myelofibrosis? I thought we could focus first on non–drug-related research that is needed to move the field forward. What do you ...
The study is evaluating AJ1-11095, a novel agent for the treatment of myelofibrosis that did not respond to or relapsed ...
"There remains a tremendous unmet need in myelofibrosis, as less than half of patients achieve SVR35 with each of the approved JAK inhibitors and many patients eventually stop responding to these ...
Mississauga: GSK has announced that Health Canada has approved Ojjaara (momelotinib) for the treatment of splenomegaly and/or ...
Mississauga, Ontario Thursday, November 14, 2024, 09:00 Hrs [IST] ...
Geron Corporation Announces Up to $375 Million in Funding with Royalty Pharma and Pharmakon Advisors
The proceeds are expected to enable us to support the commercial launch of RYTELO in the U.S. and potential launch in the EU, ...
GSK announced today that Health Canada has approved Ojjaara (momelotinib) for the treatment of splenomegaly and/or ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback